

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Nicholas Hannebery
Date of last notice	26 June 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect (1) Shares held by Robyn Gould (spouse of Richard Hannebery) Indirect (2) EG Capital Pty Limited, an entity in which Richard Hannebery has an interest Indirect (3) Silica Investments Pty Ltd, an entity in which Richard Hannebery has an interest
Date of change	11 January 2019

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p><u>Direct</u> 3,428,202 fully paid ordinary shares</p> <p>4,358,354 fully paid ordinary shares pursuant to Put/Call Option Deed and Call Option Deed</p> <p>1,000,000 performance rights vesting 31/12/17 subject to milestones</p> <p><u>Indirect (1)</u> 2,005,000 fully paid ordinary shares</p> <p><u>Indirect (2)</u> 823,228 fully paid ordinary shares</p> <p><u>Indirect (3)</u> 1,499,158 fully paid ordinary shares</p> <p>975,000 options exercisable at \$0.25 expiry 30/06/2019</p> <p>1,249,371 options exercisable at \$0.25 expiry 20/12/2020</p>
<p>Class</p>	<p>(1) Fully paid ordinary shares (2) Unlisted options, exercisable at \$0.25 (25 cents) per option, expiring 30 June 2019</p>
<p>Number acquired</p>	<p>(1) 2,595,577 Fully paid ordinary shares (2) 350,000 Unlisted options</p>
<p>Number disposed</p>	<p>-</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>(1) Deemed issue price of \$0.13 (13 cents) per share (2) Nil</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p><u>Direct</u> 6,023,779 fully paid ordinary shares</p> <p>4,358,354 fully paid ordinary shares pursuant to Put/Call Option Deed and Call Option Deed</p> <p>1,000,000 performance rights vesting 31/12/17 subject to milestones</p> <p>350,000 options exercisable at \$0.25 expiring 30/06/2019</p> <p><u>Indirect (1)</u> 2,005,000 fully paid ordinary shares</p> <p><u>Indirect (2)</u> 823,228 fully paid ordinary shares</p> <p><u>Indirect (3)</u> 1,499,158 fully paid ordinary shares</p> <p>975,000 options exercisable at \$0.25 expiry 30/06/2019</p> <p>1,249,371 options exercisable at \$0.25 expiry 20/12/2020</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>(1) Conversion of the CEO and Executive Director Mezzanine Loan into fully paid ordinary shares pursuant to Resolution 7 of the Company's 2018 Annual General Meeting, and as approved by shareholders on 14 December 2018.</p> <p>(2) Grant of options to the CEO and Executive Director of the Company under Mezzanine Facility Loan pursuant to Resolution 8 of the Company's 2018 Annual General Meeting, and as approved by shareholders on 14 December 2018.</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.